← Back
Chemours
CC · listed on the New York Stock Exchange · worth $1.99 billion
$13.19
−1.27% on Oct 29
Three insider buys in the last year, $130.6K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
149.6M shares
99% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, three insiders bought Chemours stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Executive Officer
Denise Dignam
Bought $50.5K on Aug 11 — 3,378 shares at $14.95, 1.0% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Chief Financial Officer
Shane Hostetter
Bought $50K on Aug 6 — 3,350 shares at $14.94, 3.3% of what they now own.
No earlier purchases to measure
See Remarks
Calderon Gerardo Familiar
Bought $30.1K on Aug 12 — 1,935 shares at $15.53, 3.3% of what they now own.
No earlier purchases to measure
All reports
Every insider trade and SEC report we hold for Chemours.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 12, 2025BoughtDenise DignamAug 12, 2025 · Traded Aug 8, 2025 · President & CEO+2.1%4,068 @ $12.06$49.1K
Jun 4, 2025BoughtDamian GumpelJun 4, 2025 · Traded Jun 3, 2025 · See Remarks+5.9%7,822 @ $9.95$77.8K
1 more with Pro →Analysts, earnings and news
Analysts' price target
$18.78 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26$0.42 a share+$0.00
Q1 '26$0.05 a share+$0.09
Q4 '25$0.05 a share+$0.03
Q3 '25$0.20 a share−$0.04